This bill amends section 28-405 of the Revised Statutes Cumulative Supplement, 2024, to classify tianeptine as a controlled substance under the Uniform Controlled Substances Act, addressing concerns about its misuse and health risks. The legislation aims to regulate the distribution and use of tianeptine, which is often marketed as a dietary supplement or nootropic. The bill also includes a provision to repeal the original section of the law, reflecting a comprehensive update to the controlled substances schedule and adapting legal frameworks to emerging substances.

In addition to the classification of tianeptine, the bill proposes amendments to current drug legislation by adding specific definitions and classifications for various synthetic substances, particularly those related to cannabinoids and phenethylamines. It outlines the inclusion of psychoactive substances with stimulant and depressant effects, emphasizing the need for stringent control over nonnaturally occurring substances. The bill also addresses the regulation of ephedrine and its derivatives, establishing criteria for its sale and storage, and introduces new regulations for Schedule V substances, detailing allowable quantities and labeling requirements. Overall, the bill seeks to enhance public safety by refining the legal framework governing controlled substances in response to current public health concerns.

Statutes affected:
Introduced: 28-405